Furthermore, in a secondary analysis in the paricalcitol and endothelial function in chronic kidney disease (PENNY) trial [10], we have recently observed that pentosidine modifies the sclerostin response to VDR activation by paricalcitol [11]. The gene discussed is VDR; the disease is chronic kidney disease.